Revaccination Could Benefit Children With HIV
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Revaccination Could Benefit Children With HIV

BALTIMORE, Md -- September 1, 2010 -- A review published in the September issue of the Lancet Infectious Diseases showed that most children with HIV receiving highly active antiretroviral therapy (HAART) who are vaccinated remained susceptible to vaccine-preventable diseases, but responded well to revaccination.

There remains no standard or official recommendation on revaccination of children receiving HAART, an effective intervention in reducing morbidity and mortality in HIV-infected children.

"Most children on HAART responded to revaccination, although immune reconstitution was not sufficient to ensure long-term immunity for some children," said William Moss, MD, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

"Because of the progressive effects of HIV infection on the ability of the immune system to mount an effective response, many infected children have poorer responses to vaccines than do uninfected children. In addition, fewer children infected with HIV achieve protective immunity, and those who do might experience greater and more rapid waning of immunity."

"These results suggest that children on HAART would benefit from revaccination, but levels of protective immunity might need to be monitored and some children may need additional vaccine doses to maintain protective immunity," he added.

Researchers reviewed 38 published studies to establish whether children with HIV on HAART have protective immunity to vaccine-preventable diseases and to assess short-term and long-term immune responses to vaccination of children given HAART.

Short-term was defined as <=3 months, and long-term was defined as >3 months. They found that starting HAART in infancy, before receipt of routine childhood vaccines, might preserve immunity to vaccine-preventable diseases. Currently, the World Health Organization (WHO) recommends giving most routine childhood vaccines to children infected with HIV, but does not make recommendations on revaccination.

"Continued efforts are needed to identify and treat HIV-infected children at younger ages and at earlier stages of disease," said Catherine Sutcliffe, PhD, Bloomberg School's Department of Epidemiology. "Vaccination policies and strategies for children infected with HIV on HAART should be developed in regions of high HIV prevalence to ensure adequate individual and population immunity. Without such recommendations, as treatment programs scale up and more children receive HAART and live into adolescence and adulthood, a larger proportion of these children could be susceptible to childhood diseases."

SOURCE: Johns Hopkins Bloomberg School of Public Health

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities